|
業務類別
|
Biotechnology |
|
業務概覽
|
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS. |
| 公司地址
| 10255 Science Center Drive, Suite 200, San Diego, CA, USA, 92121 |
| 電話號碼
| +1 858 732-3880 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.bhtherapeutics.com |
| 員工數量
| 63 |
| Dr. J. Jean Cui |
President, Chief Executive Officer, Director |
-- |
17/07/2026 |
| Mr. Jason Keyes |
Chief Financial Officer and Executive Vice President |
-- |
17/07/2026 |
| Mr. Vincent Liptak |
General Counsel and Executive Vice President |
-- |
17/07/2026 |
| Dr. Geoff Oxnard |
Chief Medical Officer and Executive Vice President |
-- |
17/07/2026 |
|
|
| Dr. Carl L. Gordon, C.F.A.,PhD |
Director |
17/07/2026 |
| Dr. Sheila Gujrathi, M.D. |
Director |
17/07/2026 |
| Ms. Bihua Chen, M.B.A. |
Director |
17/07/2026 |
| Dr. Sundeep Agrawal, M.D. |
Director |
17/07/2026 |
| Mr. John Schmid |
Director |
17/07/2026 |
| Dr. J. Jean Cui |
President, Chief Executive Officer, Director |
17/07/2026 |
| Dr. Y. Peter Li, PhD |
Chairman of the Board |
17/07/2026 |
| Dr. Timothy Stubbs, M.D. |
Director |
17/07/2026 |
|
|
|
|